Fears of heightened scrutiny by the FDA will be calmed by a look at historic rates of complete response letters.
Big pharma delivered 76 novel medicines to the market over the past five years, but some companies contributed more than others.
Biogen’s Aduhelm was the big one, but there are plenty of other key regulatory decisions still pending this year.
Worries about a stricter US FDA come to nothing, as last year’s approval total beats 2019’s.
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.